Statin therapy improves brachial artery endothelial function in nephrotic syndrome

Kidney International

Volumn 62, Issue 2, 2002, Pages 550-557

  Dogra, Gursharan K ^a,b   Watts, Gerald F ^a,b   Herrmann, Susan ^a,b   Thomas, Mark A B ^a,b   Irish, Ashley B ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Cardiovascular disease; Dyslipidemia; End stage renal disease; HMGCoA reductase inhibitors; Nephrosis; Proteinuria

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLYCERYL TRINITRATE; IRBESARTAN; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; QUINAPRIL; SERUM ALBUMIN; SIMVASTATIN; TRANDOLAPRIL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; BLOOD FLOW; BRACHIAL ARTERY; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PHYSIOLOGY; REGRESSION ANALYSIS; VASCULAR ENDOTHELIUM; ALBUMIN BLOOD LEVEL; ARTERY DIAMETER; ARTERY DILATATION; ARTERY ENDOTHELIUM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ECHOGRAPHY; FUNCTIONAL ASSESSMENT; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; REGIONAL BLOOD FLOW; REGRESSION ANALYSIS;

EID: 0035991539     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00483.x     Document Type: Article

References (43)

1. The increased risk of coronary heart disease associated with nephrotic syndrome
2. The nephrotic syndrome: Management, complications, and pathophysiology (chapt 3.5)
3. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study
4. Cholesterol reduction yields clinical benefit: Impact of statin trials
5. Atherogenicity of triglyceride-rich lipoproteins
6. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis
7. The role of endothelium in cardiovascular homeostasis and diseases
8. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
9. Close relation of endothelial function in the human coronary and peripheral circulations
10. Cholesterol, cholesterol lowering, and endothelial function
11. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria
12. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain
13. Impaired endothelial function in patients with nephrotic range proteinuria
14. Endothelial function in proteinuric renal disease
15. Vascular function of the peripheral circulation in patients with nephrosis
16. Lipoprotein metabolism in the nephrotic syndrome
17. The atherogenic lipoprotein phenotype: Small dense LDL and lipoprotein remnants in nephrotic range proteinuria
18. Oxidant stress in nephrotic syndrome: Comparison of F(2)-isoprostanes and plasma antioxidant potential
19. Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans
20. T-lymphocyte populations, cytokines and other growth factors in serum and urine of children with idiopathic nephrotic syndrome
21. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
22. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
23. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin
24. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase
25. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion
26. The evolving role of statins in the management of atherosclerosis
27. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
28. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome
29. Improved analysis of brachial artery ultrasound using a novel edge-detection software system
30. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis
31. New insights into lipid metabolism in the nephrotic syndrome
32. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
33. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL1
34. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries
35. Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects
36. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
37. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
38. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days
39. Albumin is an important vascular tonus regulator as a reservoir of nitric oxide
40. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: Relevance to endothelial dysfunction in hypercholesterolemia
41. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo
42. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction
43. Prognostic impact of coronary vasodilator dysfunction on adverse long- term outcome of coronary heart disease